EUCTR2014-002568-33-IT进行中（未招募）1 期
Efficacy and Safety of Faster-acting Insulin Aspart compared toNovoRapid® both in Combination with Insulin Degludec in Childrenand Adolescents with Type 1 Diabetes - onset®7
OVO NORDISK. S.P.A.0 个研究点目标入组 777 人开始时间: 2021年6月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 777
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female, 1 = age < 18 years at the time of signing informed consent and < 18 years at the time of randomisation
- •2. Diagnosed with type 1 diabetes mellitus (based on clinical judgement and supported by laboratory analysis as per local guidelines)
- •3. Ongoing daily treatment with a basal-bolus insulin regimen using basal insulin analogue or NPH insulin for at least 90 days prior to the screening visit
- •4. HbA1c = 9.5% (80 mmol/mol) analysed by the central laboratory at the screening visit
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. More than one episode of diabetic ketoacidosis requiring hospitalisation within the last 90 days prior to the screening visit
- •2. Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before screening
研究者
相似试验
进行中（未招募）
1 期
Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in Combination with Insulin Degludec in Children and Adolescents with Type 1 DiabetesDiabetes Mellitus, Type 1EUCTR2014-002568-33-DEovo Nordisk A/S750
进行中（未招募）
1 期
Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in combination with Insulin Degludec in Adults with Type 1 DiabetesMedDRA version: 20.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 1EUCTR2015-001047-36-ITOVO NORDISK. S.P.A.999
进行中（未招募）
1 期
Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in Combination with Insulin Degludec in Children and Adolescents with Type 1 DiabetesMedDRA version: 18.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 1EUCTR2014-002568-33-CZovo Nordisk A/S750
进行中（未招募）
1 期
Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in combination with Insulin Degludec in Adults with Type 1 DiabetesMedDRA version: 19.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 1EUCTR2015-001047-36-ATovo Nordisk A/S999
进行中（未招募）
1 期
Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in Combination with Insulin Degludec in Children and Adolescents with Type 1 DiabetesDiabetes Mellitus, Type 1EUCTR2014-002568-33-FIovo Nordisk A/S750